LCA-0061

Asset

Antibody–small molecule conjugate repeatedly shuttles extracellular IgE into cells for lysosomal degradation.

Stage: Phase 1
Modality: Other
Target: Not known; 6
Indications: 0
Trials: 1
Developer

Indications

6

Allergic asthma
Phase 1, lyciatx.com, 10 Oct 2026
Allergic rhinitis
Phase 1, lyciatx.com, 10 Oct 2026
Chronic rhinosinusitis with nasal polyps
Phase 1, lyciatx.com, 10 Oct 2026

3 more

In the full profile

Owner and partners1

Every asset’s record: target, stage, trials and the evidence behind it.